International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

Adverse Effects of Areca Nut (Kwai) and Tobacco Use: A Comprehensive Review

Dr Reuben P Syiem

Date of Submission: 10-05-2025 Date of Acceptance: 20-05-2025

Background: Areca nut (also known as betel nut or kwai in Northeast India) and tobacco are among the most widely used psychoactive substances globally, embedded in cultural traditions yet linked to severe health consequences. Both areca nut chewing and tobacco use are recognized as significant public health challenges due to their association with oral diseases, systemic illnesses, and cancers. Understanding their adverse effects, particularly the molecular and cellular mechanisms of toxicity and the epidemiological impact in high-prevalence regions like Northeast India, is crucial for developing targeted public health interventions.

Objective: To review and synthesize current evidence on the adverse health effects of areca nut and tobacco use, with an emphasis on pharmacological mechanisms of toxicity, clinical impacts across organ systems, and public health consequences. Special attention is given to cultural context, regulatory aspects, and epidemiological data from Northeast India.

Methods: A comprehensive literature search was conducted focusing on peer-reviewed studies, review articles, and official reports (WHO, IARC, and national surveys such as GATS) published in the last two decades. Key terms included "areca nut toxicity," "betel quid health effects," "tobacco adverse effects," and "Northeast India tobacco areca epidemiology." Both human clinical studies and animal/in-vitro studies were included to elucidate pharmacodynamic mechanisms. Data specific to Northeast India were extracted from regional surveys and cancer registries. All sources were screened for credibility and relevance, and references are cited in Vancouver style.

Results: Areca nut contains alkaloids (e.g., arecoline) and polyphenols that induce pharmacodynamic effects (euphoria, cholinergic activation) and cellular changes (fibroblast activation, oxidative stress) contributing to oral submucous fibrosis and carcinogenesis. Tobacco use (smoked and smokeless) delivers nicotine and numerous carcinogens (e.g., nitrosamines, polycyclic aromatic hydrocarbons) that cause DNA damage, inflammation, and addiction neurocircuitry changes. Epidemiological studies link areca nut chewing to oral premalignant conditions and metabolic disorders, while tobacco smoking is causally linked to cancers of the lung, oral cavity, and multiple organs, as well as cardiovascular and respiratory diseases. Combined use (betel quid with tobacco) synergistically increases risk of oral and esophageal cancers. Clinical impacts include oral mucosal lesions, periodontal disease, systemic hypertension and atherosclerosis, dysglycemia and type 2 diabetes, adverse reproductive outcomes (low birth weight, stillbirth), and neuropsychiatric effects including dependence syndromes. Northeast India exhibits an especially high burden: over 40% of adults use tobacco (predominantly smokeless forms) and betel quid chewing is pervasive, correlating with some of the highest oral cancer rates in India. Regulatory measures (such as tobacco control laws and partial bans on areca-tobacco mixtures) exist but face challenges in implementation amid strong cultural acceptance.

Conclusion: Both areca nut and tobacco use impose significant adverse effects on oral and systemic health through well-characterized toxicological mechanisms. The dual endemic use of kwai (areca quid) and tobacco in regions like Northeast India has led to disproportionate oral cancer and metabolic disease burdens. Strengthened regulatory policies, culturally tailored cessation programs, and further research into molecular mechanisms are urgently needed to mitigate these health impacts. Public health strategies must address both substances in tandem to reduce morbidity and mortality associated with their use.

INTRODUCTION

Tobacco and areca nut are two substances of major public health concern worldwide. Tobacco use is the leading preventable cause of death, responsible for over 8 million deaths per year globally according to the World Health Organization [1]. Areca nut (the seed of Areca catechu, often chewed wrapped in betel leaf

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

as betel quid) is estimated to be used regularly by 600 million people, roughly 10% of the world's population, making it the fourth most common psychoactive substance after caffeine, alcohol, and nicotine [2,3]. These habits have deep cultural roots – for instance, chewing kwai (betel quid) is an integral social custom in Northeast India – but they carry well-documented adverse health effects.

Both areca nut chewing and tobacco (in smoked or smokeless forms) have been conclusively linked to oral and systemic diseases. The International Agency for Research on Cancer (IARC) classifies tobacco smoking, smokeless tobacco, and areca nut (with or without added tobacco) as carcinogenic to humans (Group 1 carcinogens) [4,5]. Epidemiologic data show strong associations with malignancies such as oral squamous cell carcinoma, esophageal cancer, and others in populations where these substances are prevalent. In parts of India and Southeast Asia, oral cancer rates are among the highest in the world, largely attributable to the widespread practices of betel quid chewing and tobacco use. Northeast India in particular suffers a disproportionately high incidence of oral and esophageal cancers, which has been correlated with the regional popularity of betel nut chewing (often combined with tobacco) [6,7]. Beyond cancer, tobacco is known to cause cardiovascular, respiratory, and metabolic diseases, while chronic areca nut use leads to oral precancerous conditions (like oral submucous fibrosis), metabolic derangements, and other systemic effects [3,8]. There is also concern about the combined use exacerbating health risks.

This review provides a comprehensive overview of the adverse effects of areca nut and tobacco. We discuss the cultural and historical context of their use, current regulatory frameworks, and delve into the molecular mechanisms of toxicity (pharmacodynamics and cellular effects). Evidence from clinical studies and experimental models is summarized to link these mechanistic insights with observed health outcomes. We then detail the clinical impacts on various organ systems – oral health, systemic effects, metabolic, reproductive, and neuropsychiatric consequences – arising from areca nut and tobacco consumption. Finally, public health and epidemiological implications are examined, with emphasis on the situation in Northeast India, to highlight the need for targeted interventions in high-burden communities.

Cultural and Historical Context

Areca Nut (Betel Quid): Chewing areca nut has a history spanning thousands of years in South and Southeast Asia. Ancient Sanskrit texts and historical records describe betel chewing in medicinal, social, and religious contexts in the Indian subcontinent. The practice involves chewing the nut often wrapped in a betel leaf along with slaked lime and sometimes spices or tobacco, creating a quid (paan). This custom spread across Asia and to parts of the Pacific and Africa, becoming deeply ingrained in many cultures [9]. In Northeast India, the tradition of offering kwai (areca nut with betel leaf) to guests is a symbol of hospitality and friendship. Betel chewing is initiated early in life as a socially acceptable habit; for example, very high prevalence of betel nut use has been documented among adolescents and young adults in Meghalaya and other northeastern states [10]. The practice is often believed to aid digestion, provide energy, and freshen breath, contributing to its sustained cultural popularity. However, the benign perception of betel quid contrasts with its now-known health risks.

Tobacco: Tobacco was introduced to South Asia in the 17th century and rapidly assimilated into local customs. Over time, India developed its own tobacco products – from smoking forms like bidis (hand-rolled leaf cigarettes) and hookah (waterpipe) to smokeless forms such as khaini, zarda, and gutkha (chewable mixtures of tobacco, areca nut, and flavorings). In many regions, including the Northeast, tobacco is often chewed in combination with betel quid. Use of tobacco, like areca nut, can be interwoven with social and ritual practices (e.g., tobacco offerings in some tribal rituals). By the 20th century, commercial cigarettes and packaged smokeless tobacco products became widespread, increasing consumption. Cultural acceptance of tobacco remains high in certain communities – for instance, some indigenous tribal populations in Northeast India have among the highest rates of tobacco use in the country [10]. This historical and cultural entrenchment of areca nut and tobacco complicates efforts to curb their use, as chewing and smoking are not merely habits but part of social identity and tradition for many groups.

Regulatory Aspects

Regulatory approaches to mitigate the harms of areca nut and tobacco face unique challenges. **Tobacco control** is relatively more

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

established: The WHO Framework Convention on Tobacco Control (WHO-FCTC) came into force in 2005, committing signatory countries (including India) to evidence-based measures such as taxation, advertising bans, health warnings, and smoke-free public spaces [11]. In India, the Cigarettes and Other Tobacco Products Act, 2003 (COTPA) prohibits tobacco advertising, restricts sales to minors, mandates pictorial health warnings on packaging, and bans smoking in public places [12]. Over the past decade, India has implemented large graphic warnings on cigarette and smokeless tobacco packages and increased taxes on tobacco products in line with WHO recommendations. Enforcement of these laws, however, varies by region.

Smokeless tobacco and gutkha bans: Given the high use of smokeless tobacco (often combined with areca nut) in South Asia, regulatory attention has also focused on these products. India took the notable step of banning the manufacture and sale of **gutkha** – a prepackaged mixture of areca nut, tobacco, lime, and flavorings – by invoking the Food Safety and Standards Act (FSSA) in 2011–2012. This effectively classified gutkha as an adulterated food product unfit for consumption. Following a landmark case and central government directives, all Indian states and union territories had imposed gutkha bans by 2013 [12]. These bans aimed to curb the rampant oral cancer and precancer associated with chewable tobacco products. However, enforcement has been challenging; manufacturers have responded by selling areca nut and tobacco in separate packets (to be mixed by users), thereby exploiting legal loopholes. Moreover, pure areca nut products (e.g., scented or flavored pan masala without tobacco) remain legal and widely available, often without strong health warnings. Areca nut itself is not regulated under international drug control conventions, despite its carcinogenic status, due to its cultural ubiquity[12].

Regional implementation: In Northeast India, which has some of the highest prevalence of chewing habits, enforcement of tobacco control policies presents additional difficulties. Nonetheless, national programs such as the National Tobacco Control Programme (NTCP) have been rolled out in northeastern states, and public notifications enforcing COTPA and the gutkha ban have been issued [13]. Some local governments have launched awareness campaigns about the dangers of betel quid chewing and smoking. For example, authorities in states like Assam and Meghalaya have attempted to regulate the sale of tobacco near educational institutions and run outreach in communities. However, the deeply rooted social acceptance of kwai-tobacco chewing means that regulations alone have limited impact. Strengthening enforcement (e.g., against illicit gutkha sales) and integrating culturally sensitive education campaigns are ongoing needs. Internationally, there is growing recognition of areca nut as a public health issue; experts have called for interventions similar to tobacco control for betel quid, including possibly adding warning labels to areca products and public education in high-use regions[13].

Mechanisms of Toxicity: Pharmacodynamics and Cellular Effects

Areca Nut (Arecoline and related compounds): The primary psychoactive ingredient in areca nut is the alkaloid arecoline. Pharmacodynamically, arecoline is a partial agonist at muscarinic acetylcholine receptors and has mild parasympathomimetic effects. Chewing betel quid releases arecoline, which is rapidly absorbed through the oral mucosa and can cross the blood–brain barrier. Users experience a mild euphoria, heightened alertness, and a warming sensation; these effects are attributed to arecoline's action on central cholinergic and dopaminergic pathways, as well as peripheral release of adrenaline/noradrenaline. Arecolinealso has an anxiolytic or mood-elevating effect in some users (historically leading to its use in folk medicine for treating anxiety and GI disorders). Chronic exposure, however, leads to tolerance and dependence. Regular chewers exhibit a withdrawal syndrome – including irritability, anxiety, and craving – upon abstinence, indicating that areca nut can induce a dependence syndrome similar to other psychoactive substances. Rare cases of psychosis after abrupt cessation have even been reported in heavy users[14].

On a cellular level, areca nut constituents exert pro-fibrotic, genotoxic, and inflammatory effects. Arecoline and other areca alkaloids stimulate fibroblasts in the oral submucosa to overproduce collagen while simultaneously inhibiting collagen-degrading enzymes. Polyphenolic compounds in the nut (such as tannins) cause collagen cross-linking and reduce its turnover, while the high copper content of areca nut (released during chewing) upregulateslysyl oxidase, further

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

promoting collagen fiber formation. The result is a progressive fibrosis of the oral mucosa (oral submucous fibrosis, OSMF), characterized by stiff, inelastic mucosal tissue and risk of malignant transformation. Arecoline has been shown to upregulate pro-fibrotic and inflammatory cytokines (e.g., TGF-β, IL-6, TNF-α, PGE_2) in oral fibroblasts and keratinocytes, driving a chronic wound-healing response that underpins OSMF and oral precancer development [14]. Concurrently, areca nut use generates reactive oxygen species in the oral cavity due to auto-oxidation of areca catechins in the presence of slaked lime (alkaline pH) and transition metals. This oxidative stress leads to DNA strand breaks and chromosomal damage in oral epithelial cells; accordingly, habitual chewers show higher frequencies of micronuclei and sister chromatid exchanges in oral cells and circulating lymphocytes. Areca-derived nitrosamines (e.g., N-nitrosoguvacoline), formed by nitrosation of arecoline and related alkaloids in saliva, are proven mutagens and have been implicated in the initiation of oral and esophageal cancers. These compounds form DNA adducts and cause mutations in oncogenes/tumor suppressors. Notably, areca nut alone (even without tobacco) is sufficient to cause oral cancer; epidemiologic studies in populations who chew betel quid without tobacco have confirmed a significantly elevated oral cancer risk. Mechanistically, beyond direct genotoxicity, arecoline exposure can induce epigenetic alterations (e.g., DNA methylation changes) and immune dysregulation that may facilitate oncogenesis [15]. Animal studies reinforce these findings: chronic arecoline administration in rodents leads to multi-organ fibrotic changes (e.g., cardiac fibrosis via TGF-β mediated pathways), developmental toxicity (fetal abnormalities and low birth weight in animal models), and tumor formation in organs like the liver and pancreas [15]. In summary, the pharmacologic effects of areca nut (stimulation and dependence) are intertwined with its toxic effects at the cellular level – fibrosis, DNA damage, and carcinogenesis – largely driven by arecoline and synergistic components of the betel quid [16].

Tobacco (Nicotine and smoke constituents): The chief active component of tobacco is nicotine, an alkaloid that exerts its pharmacological effects by binding to nicotinic acetylcholine receptors (nAChRs) in the central and peripheral nervous system. Nicotine absorption is rapid via pulmonary alveoli when smoked and through the oral/nasal mucosa when used in smokeless forms. Acute nicotine intake causes release of neurotransmitters such as dopamine, acetylcholine, and glutamate in the brain's reward pathways, leading to pleasurable sensations and reinforcement of use. This neuropharmacological action underlies tobacco's high addictive potential – repeated use causes neuroadaptation, and cessation triggers withdrawal symptoms (irritability, anxiety, restlessness, increased appetite, etc.) [17]. Peripherally, nicotine stimulates the sympathetic nervous system, causing transient increases in heart rate, blood pressure, and cardiac contractility. It also raises blood glucose by promoting catecholamine-mediated glycogenolysis and possibly inducing insulin resistance with chronic exposure [17]. These sympathomimetic effects contribute to the cardiovascular strain seen in habitual smokers.

In addition to nicotine, tobacco smoke contains a complex mixture of toxins. Combustion of tobacco releases over 7,000 chemicals, of which at least 70 are established carcinogens [17]. Key classes of carcinogens include polycyclic aromatic hydrocarbons (PAHs) and tobacco-specific N-nitrosamines (TSNAs) such as NNK (4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone) and NNN (N-nitrosonornicotine). These carcinogens form DNA adducts in exposed cells, leading to mutations in critical genes (for example, TP53 tumor suppressor mutations in lung and oral cancers have been linked to smoking-related DNA damage) [18]. Reactive aldehydes (like acrolein and formaldehyde) in smoke further contribute to DNA and protein damage, while heavy metals (arsenic, cadmium, lead) accumulate in tissues causing toxic effects. In smokeless tobacco (chewing tobacco, snuff), TSNA levels are especially high, directly exposing oral mucosa to carcinogens; this explains the strong association of smokeless tobacco with oral, pharyngeal, and esophageal cancers [5]. Nicotine itself, though not a direct carcinogen, can promote tumor growth and angiogenesis by activating nicotinic receptors on epithelial and endothelial cells, which may facilitate cancer progression in smokers.

Beyond carcinogenesis, tobacco's toxicodynamics involve inflammation and oxidative stress. Tobacco smoke is a potent irritant; chronic inhalation incites inflammation in the airways and lungs, with recruitment of neutrophils and macrophages that release proteases and free radicals, contributing to chronic obstructive pulmonary disease (emphysema, chronic bronchitis). Systemically, smokers exhibit elevated

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

markers of oxidative stress and inflammation (e.g., C-reactive protein), which are linked to endothelial dysfunction and atherosclerosis development. Carbon monoxide in smoke binds hemoglobin to form carboxyhemoglobin, reducing oxygen delivery and causing tissue hypoxia – a factor in cardiovascular disease and adverse pregnancy outcomes. In pregnancy, carbon monoxide and nicotine reduce placental blood flow, leading to fetal growth restriction and low birth weights in smoking mothers [17]. Nicotine exposure in utero and in early life can also have neurodevelopmental effects on the fetus/infant. In males, long-term tobacco use has been associated with reduced sperm quality and infertility, likely due to nicotine-induced vasoconstriction and DNA damage in germ cells [8]. Immunologically, tobacco impairs host defenses: smoking is associated with reduced function of respiratory cilia and immune cells, increasing susceptibility to infections and attenuating wound healing.

In summary, nicotine drives the addictive and acute hemodynamic effects of tobacco, while a myriad of other chemical constituents drive its chronic pathogenic effects. The mechanisms of toxicity include direct genetic damage leading to cancer, chronic inflammation and oxidative injury leading to organ damage (lungs, vasculature), and metabolic and endocrine disruption contributing to conditions like cardiovascular disease and diabetes. These mechanistic insights align with epidemiological evidence of markedly elevated risks of malignancies, cardiovascular events, respiratory disease, and other health issues among tobacco users [17].

Evidence from Human Clinical Studies and Animal/In-Vitro Studies

Human studies: Abundant epidemiological evidence links both areca nut and tobacco to adverse health outcomes. In case-control and cohort studies across South Asia and other regions, habitual betel quid chewing (with or without tobacco) is associated with a greatly increased risk of oral potentially malignant disorders and cancers. A meta-analysis by Guha et al. found that ever-chewers of betel quid had significantly higher odds of oral and oropharyngeal cancer compared to never-users (with pooled odds ratios in the range of 3–7, varying by presence of tobacco in the quid) [6]. Importantly, even betel quid without tobacco was carcinogenic, corroborating earlier observations by IARC. Chewers also have elevated incidence of esophageal cancer in high-prevalence areas such as Northeast India [7]. Clinically, oral submucous fibrosis (OSMF) is frequently seen in areca nut users; this debilitating fibrotic condition has a reported malignant transformation rate on the order of 7–13% in long-term studies [14]. Human studies have also linked areca nut use to non-malignant diseases: for example, epidemiological research in Taiwan has identified chewing areca nut as an independent risk factor for metabolic syndrome and type 2 diabetes, with dose-dependent increases in diabetes prevalence and odds of hyperglycemia in habitual chewers [8]. Areca nut use during pregnancy has been associated with adverse outcomes (e.g., low birth weight and preterm birth) in observational studies [18]. On the tobacco side, the evidence is overwhelming: prospective cohort studies (such as the landmark British Doctors' Study and American Cancer Society's Cancer Prevention Study) demonstrated that long-term cigarette smokers face 10–20 times the risk of lung cancer and a dramatically higher overall mortality than non-smokers [19]. Smoking is causally linked to cancers of at least a dozen sites (lung, oral cavity, larynx, esophagus, stomach, pancreas, bladder, cervix, etc.), as well as cardiovascular disease, stroke, chronic lung disease, and numerous other conditions [5]. Smokeless tobacco use, prevalent in South Asia, is also firmly linked to oral, pharyngeal, and esophageal cancers: an Indian pooled analysis found a 2–3 fold higher risk of oral cancer in users of chewing tobacco formulations like mishri, khaini, and gutkha [20]. Clinical studies further show that tobacco cessation leads to reduction in risk over time (e.g., a 50% decline in myocardial infarction risk within 1–2 years of quitting smoking), underscoring the causal role of tobacco in these diseases [17].

Animal and in vitro studies: Experimental models have provided insight into the pathogenic mechanisms of areca nut and tobacco constituents. Areca nut extracts and arecoline have shown mutagenic and genotoxic effects in various in vitro assays, producing DNA damage in human cell lines and inducing micronuclei formation in cultured cells. In animal models, chronic administration of areca nut or its alkaloids causes pathology consistent with human disease: rodents fed arecoline develop fibrosis in organs (e.g., liver, heart) [16], and hamsters exposed to betel quid (with tobacco) develop tumors in the oral mucosa and esophagus (paralleling human oral cancer) [4]. Certain areca-derived nitrosamines have been

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

tested in animals and found to be potent carcinogens (for instance, N-nitrosoguvacoline induces tumors in the pancreas and lung of rodents) [4]. Tobacco carcinogenesis is similarly reproducible in the laboratory. Classic experiments in the 1950s showed that painting cigarette tar on mouse skin induces malignant tumors, establishing the presence of carcinogens in tobacco. Specific tobacco smoke chemicals have clear carcinogenicity in vivo: for example, the tobacco-specific nitrosamine NNK produces lung adenocarcinomas in rodents, and benzo[a]pyrene (a representative PAH) causes tumors at sites of application in animals [18]. Inhalation of whole cigarette smoke in controlled exposures leads to emphysematous lung changes in rats and mice, modeling COPD. Moreover, nicotine administered to pregnant animals results in impaired fetal growth and developmental toxicity, mirroring epidemiological observations in humans. The concordance between experimental findings and epidemiological data reinforces the causal link between areca nut/tobacco and the spectrum of diseases observed. In vitro studies also shed light on molecular mechanisms – for example, exposing human oral keratinocytes to arecoline triggers alterations in gene expression (upregulating fibrosis- and cancer-related pathways), while treating vascular endothelial cells with cigarette smoke extract impairs their function and promotes inflammation. Such studies, together with animal research, provide biological plausibility and mechanistic understanding for the clinical patterns seen in human populations.

Clinical Impacts on Organ Systems

Oral and Dental Health: The most immediate and well-documented impacts of areca nut and tobacco use manifest in the oral cavity. Chronic chewing of areca nut (with or without added tobacco) causes a range of oral mucosal changes. Staining of teeth and gingiva with a reddish-brown hue is common due to areca-tannin pigments. Dental attrition (wear of teeth) and periodontal disease are more frequent in long-term chewers, partly from the mechanical trauma and the irritant effects of the quid [3]. Areca nut is a principal etiological factor for oral submucous fibrosis, as discussed, which presents with trismus (restricted mouth opening), burning sensation, and fibrosis of the oral mucosa; OSMF significantly increases oral cancer risk [14]. Tobacco use further exacerbates oral health problems. Smokers have a substantially elevated risk of periodontitis (gum infection and bone loss), tooth loss, and delayed wound healing in the mouth compared to non-smokers [17]. Smoking and smokeless tobacco both cause characteristic dental staining; smokeless tobacco users often develop gingival recession and localized gum lesions (e.g., tobacco pouch keratosis) at the site of quid placement. Oral leukoplakia (white precancerous patches) and erythroplakia can be induced by either tobacco or betel quid habits, and carry a risk of progression to malignancy. Indeed, India bears a high burden of oral squamous cell carcinoma largely attributable to these practices [6]. Combined use of tobacco and areca nut (as in gutkha or tobacco-laden betel quid) confers synergistically higher risk for oral cancer than either alone, due to the amalgamation of carcinogens [5]. On a positive note, clinical observations indicate that cessation of chewing and smoking can lead to some reversal of precancerous lesions and improvements in periodontal health, underscoring the importance of early intervention [17].

Systemic and Cardiovascular Effects: The impact of tobacco extends to virtually every organ system. Cardiovascular disease is one of the major consequences of chronic tobacco use. Smoking promotes atherosclerosis (hardening and narrowing of arteries) by damaging endothelial cells, increasing oxidative stress, and altering lipid profiles. Smokers have 2–4 times the risk of coronary heart disease and stroke compared to non-smokers, and this risk rises further in those who both smoke and chew tobacco [17]. Even smokeless tobacco, though free of combustion byproducts, delivers high doses of nicotine that can contribute to hypertension and endothelial dysfunction. Areca nut chewing has also been linked to cardiovascular stress: acute effects include tachycardia and elevated blood pressure, and epidemiological studies suggest an association between betel nut use and hypertension [8]. Some chronic chewers show ECG changes and ventricular arrhythmias, though direct causal evidence for areca nut causing heart disease is still emerging. Beyond the heart, tobacco smoking is notorious for its impact on the lungs. It is the primary cause of chronic obstructive pulmonary disease (COPD) – a progressive illness of emphysema and chronic bronchitis – resulting from the chronic inflammation and protease release provoked by smoke inhalation. Smokers have significantly reduced lung function and are at risk of respiratory infections (like pneumonia and

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

tuberculosis) due to impaired mucociliary clearance and immune defenses. In contrast, areca nut by itself is not inhaled and thus does not cause lung disease, but betel quid chewing can aggravate asthma in susceptible individuals (via arecoline-induced bronchoconstriction). Systemically, both substances contribute to an overall pro-inflammatory state. Chewing and smoking have been associated with elevated markers of systemic inflammation, which can exacerbate co-morbid conditions.

Metabolic and Endocrine Effects: Emerging evidence indicates that both tobacco and areca nut use can detrimentally affect metabolic health. Cigarette smoking has been identified as an independent risk factor for type 2 diabetes mellitus [17]. Nicotine and other constituents of tobacco may induce insulin resistance and impair glucose metabolism; smokers tend to have higher hemoglobinA1c levels and a greater risk of developing diabetes than non-smokers. Similarly, population studies link areca nut chewing to metabolic syndrome – a cluster of insulin resistance, hypertension, and dyslipidemia. As noted, habitual betel nut chewers in Asia have higher rates of type 2 diabetes [8]; proposed mechanisms include arecoline-induced catecholamine release (leading to hyperglycemia) and antagonism of GABA receptors that results in increased glucagon secretion. Areca nut's effect on appetite and weight is complex: while some users report appetite suppression and maintain lower body weight, chronic chewing is associated with central obesity and dysregulated lipid profiles in certain studies [15]. Endocrine disturbances have also been reported anecdotally with areca nut use, such as altered thyroid function and reproductive hormone levels, though robust data are limited [15]. In summary, both smoking and chewing can contribute to metabolic derangements that increase the risk of diabetes and cardiovascular complications.

Reproductive and Developmental Effects: The use of tobacco or areca nut during pregnancy poses significant risks to maternal and fetal health. Tobacco smoking in pregnancy is well-known to cause intrauterine growth restriction, leading to babies with lower birth weight on average; it also increases the risk of miscarriage, stillbirth, preterm delivery, and complications such as placental abruption. These outcomes are largely attributed to nicotine-mediated vasoconstriction of uteroplacental blood vessels and carbon monoxide-induced fetal hypoxia, as well as direct toxic effects on the developing fetus [17]. Chewing smokeless tobacco while pregnant similarly doubles the risk of low-birth-weight infants and can lead to preterm births, as evidenced by studies in India where smokeless tobacco use is prevalent among women [20]. Areca nut use by expectant mothers, as highlighted in a recent systematic review, is significantly associated with reduced birth weight (pooled OR ~1.75 for low birth weight) and has been linked to preterm labor [21]. Animal studies corroborate these findings (nicotine exposure causing fetal growth retardation, and arecoline proving embryotoxic in animal models). Reproductively, males who smoke are at increased risk for infertility and sexual dysfunction; tobacco's vasculature effects can lead to erectile dysfunction and the toxicants in smoke can impair sperm count and motility. Chronic betel chewing might also impact male fertility – in animal experiments it reduced testicular weight and sperm quality, although human data are sparse. There is some evidence that maternal betel chewing could influence neonatal health beyond birth weight, possibly affecting infant neurodevelopment, but further research is needed. Overall, public health guidelines strongly advise cessation of any tobacco or areca nut use during pregnancy to protect maternal and child health.

Neuropsychiatric Effects: The psychoactive nature of areca nut and tobacco means they significantly affect the brain and behavior. Both substances produce dependence syndromes recognized in medical classifications (nicotine dependence is established in DSM-5, and areca nut dependence syndrome is documented in ICD-10). Users of betel nut often find it habit-forming; surveys in Northeast India have noted that a majority of daily chewers report difficulty in quitting and experience withdrawal symptoms [22]. Nicotine addiction from tobacco is one of the hardest addictions to break, comparable to opioids in relapse rates. The neurochemical basis, as discussed, involves dopamine release in reward circuits. Beyond addiction, long-term use of these substances has been linked to mental health impacts. Tobacco smokers have higher rates of anxiety and depressive disorders than non-smokers, though part of this association is due to nicotine's temporary relief of withdrawal symptoms and smokers using cigarettes as self-medication. There is evidence that quitting smoking can improve mental health outcomes in the long run, with

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

reduced anxiety and stress levels reported post-cessation. Areca nut's impact on mental health is less studied, but some reports suggest chronic high-dose chewing may be associated with exacerbation of anxiety or psychotic symptoms in susceptible individuals. One intriguing aspect is the historical use of areca nut for its nootropic and mood-elevating effects – it has mild anti-depressant properties via cholinergic activation, which might explain its appeal to individuals under stress. However, heavy use can lead to paradoxical effects; for instance, cases of areca nut withdrawal psychosis indicate the substance's profound neurochemical influence. There is also a social dimension: in youth, areca nut chewing (especially sweetened formulations) can act as a gateway to tobacco use [19], introducing adolescents to psychoactive substance use and increasing the likelihood of later tobacco smoking. From a neurological standpoint, chronic smoking is a risk factor for stroke and has been associated with cognitive decline in older age. While some studies paradoxically suggested lower Parkinson's disease incidence in smokers (attributed to nicotine's effects on neurotransmitters), this does not outweigh the numerous adverse neurological outcomes linked to tobacco. In summary, both tobacco and areca nut significantly impact the brain – reinforcing their own use through addiction, and potentially modulating mood and cognitive function – which necessitates addressing the psychological aspects in cessation programs.

Public Health and Epidemiological Consequences

The tandem use of areca nut (betel quid) and tobacco presents a substantial public health challenge, especially in regions like Northeast India where these practices are embedded in the social fabric. **Burden of disease:** Globally, tobacco is a leading cause of morbidity and mortality, accounting for an estimated 8 million deaths annually (from cancer, cardiovascular, respiratory, and other diseases) [1]. Areca nut, while not quantified in global mortality in the same way, contributes to a high burden of oral potentially malignant disorders and cancers in South Asia. In India, oral cancer is among the most common cancers in men and women, with the highest incidence rates observed in states of the Northeast where betel quid chewing and tobacco use are almost ubiquitous. According to an ICMR report, the Northeast region has the highest proportion of tobacco-related cancers in the country, with nearly half of male cancers and a quarter of female cancers in some states attributable to tobacco use [7]. Oral and esophageal cancers, in particular, are remarkably prevalent. For example, Assam has historically recorded esophageal cancer rates well above the national average, correlating with the widespread chewing of betel nut and tobacco in the population [6,7].

Epidemiological patterns in Northeast India: Surveys such as the Global Adult Tobacco Survey (GATS) indicate that overall tobacco use in Northeast India is significantly higher than the national average, driven largely by smokeless tobacco and betel quid chewing. More than 40% of adults in this region use some form of tobacco [13]. In states like Meghalaya, Mizoram, and Tripura, the majority of men and a substantial proportion of women chew betel quid, often with tobacco. This has resulted in a visible public health impact: these states have among the highest oral cancer incidence and mortality rates in India. The cultural norm of starting betel chewing early (often in teenage years) means that precancerous lesions like leukoplakia or OSMF are being diagnosed in younger cohorts than elsewhere. Additionally, the dual use of smoked tobacco (cigarettes or bidis) and smokeless forms is common, compounding risks (for instance, dual users have higher risks of head-neck cancers and other diseases than exclusive users of either). The intertwining of areca nut with tobacco in products like gutkha has created a synergistic epidemic of addiction and disease. From a public health perspective, this calls for combined interventions.

Economic and social implications: Both areca nut and tobacco use impose economic burdens on individuals and healthcare systems. In lower socio-economic groups, which constitute a significant portion of chewers and smokers in Northeast India, a considerable part of household income may be spent on these substances, even as these habits contribute to ill health and lost productivity. The treatment of oral cancers, often diagnosed at late stages, is expensive and not readily accessible in many northeastern regions, leading to high mortality and suffering. Socially, efforts at cessation face barriers because chewing kwai and smoking are deeply ingrained social habits, sometimes tied to identity and community rituals.

Public health responses: Efforts to address these issues in Northeast India and similar settings involve both broad tobacco control strategies and

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

targeted initiatives. The government and NGOs have launched awareness campaigns in local languages about the harms of betel quid chewing. School-based education programs aim to dissuade youth from picking up these habits, emphasizing the consequences such as mouth cancers and disfigurement from OSMF. Screening programs for oral precancer (for example, regular oral examinations by health workers) are being instituted in some high-risk districts to catch lesions early. Cessation support specifically tailored to smokeless tobacco and areca nut users is also being developed – including behavioralcounseling and, experimentally, nicotine replacement therapy or other pharmacologics for chewable tobacco addiction. Culturally sensitive approaches, such as engaging community leaders and using local customs (e.g., substituting kwai with a non-harmful alternative in ceremonies), are being explored to reduce usage. On a policy level, while the gutkha ban is in place, enforcement could be strengthened by cracking down on illegal sales and educating vendors. The Northeast's experience also underscores the need for national programs (like NTCP) to allocate additional resources to high-prevalence areas and possibly extend regulation to areca nut itself (for instance, by mandating health warnings on areca nut product packaging and prohibiting marketing that targets youth).

Global perspective: The issues seen in Northeast India reflect a broader global public health concern in betel quid chewing populations (e.g., Bangladesh, Sri Lanka, parts of Southeast Asia, China, and Pacific islands). The World Health Organization has noted that areca nut chewing, often combined with tobacco, is the fourth most common addictive habit worldwide and a cause of significant preventable morbidity. However, unlike tobacco and alcohol, areca nut has not received commensurate international regulatory attention. The inclusion of areca nut in international health agendas – for example, via WHO non-communicable disease (NCD) programs – is crucial. Some countries (such as Taiwan) have implemented localized campaigns resulting in reductions in betel quid use and subsequent declines in oral cancer rates, demonstrating that progress is possible. Sharing such best practices could benefit regions like Northeast India.

In conclusion, the adverse effects of areca nut (kwai) and tobacco use represent a confluence of cultural, behavioral, and biological factors that challenge public health. The evidence is clear that both substances contribute heavily to oral cancers, systemic diseases, and psychosocial problems. Combating this twin epidemic requires a multifaceted approach – combining scientific insights from pharmacology and epidemiology with culturally informed prevention and policy measures. Especially in high-burden areas, intensified efforts in education, regulation, and healthcare delivery can yield meaningful reductions in disease and ensure that cultural practices evolve towards safer traditions for future generations.

REFERENCES

[1]. World Health Organization. **Tobacco**: Key facts. Geneva: WHO; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/tobacco (accessed 2024 May 8).
[2]. Gupta PC, Ray CS. Epidemiology of betel quid usage. Ann Acad Med Singap. 2004;33:31–6.
[3]. Dangore-Khasbage S, Bhowate RR, Khubchandani M. Chemical composition of areca nut and its adverse effects on human health. Cureus. 2023;15(8):e43739.
[4]. International Agency for Research on Cancer (IARC) Working Group. IARC Monographs on the Evaluation of Carcinogenic Risks to Humans, Volume 85: Betel-quid and Areca-nut Chewing and Some Areca-nut-derived Nitrosamines. Lyon: IARC; 2004.
[5]. International Agency for Research on Cancer (IARC) Working Group. IARC Monographs, Volume 100E: Personal Habits and Indoor Combustions (Tobacco Smoking, Smokeless Tobacco). Lyon: IARC; 2012.
[6]. Guha N, Warnakulasuriya S, Vlaanderen J, Straif K. Betel quid chewing and the risk of oral and oropharyngeal cancers: a meta-analysis with implications for prevention. Int J Cancer. 2014;135(6):1433–43.
[7]. ICMR-NCDIR (Indian Council of Medical Research – National Centre for Disease Informatics and Research). Profile of Cancer and Related Health Indicators in the North East Region of India – 2021. Bangalore: ICMR-NCDIR; 2021.
[8]. Tung T-H, Chiu Y-H, Chen L-S, et al. A population-based study of the association

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May–June 2025, pp: 727-736 www.ijprajournal.com ISSN: 2456-4494

between areca nut chewing and type 2 diabetes mellitus in men. Diabetologia. 2004;47(10):1776–81.

[9]. Ahuja SC, Ahuja U. Betel leaf and betel nut in India: history and uses. Asian Agri-History. 2011;15(1):13–35.

[10]. Xaxa V. Report of the High-Level Committee on Socio-Economic, Health and Educational Status of Tribal Communities of India. New Delhi: Ministry of Tribal Affairs, Government of India; 2014.

[11]. World Health Organization. WHO Framework Convention on Tobacco Control. Geneva: WHO; 2003.

[12]. Arora M, Madhu R. Banning smokeless tobacco in India: policy analysis. Indian J Cancer. 2012;49(4):365–70.

[13]. Kaul S, Jain DC, Garg R, et al. Tobacco control policies in India: implementation in the North-East region. Indian J Public Health. 2016;60(3):219–25.

[14]. Rajalalitha P, Vali S. Molecular pathogenesis of oral submucous fibrosis – a collagen metabolic disorder. J Oral Pathol Med. 2005;34(6):321–8.

[15]. Liu H, Zheng H, Zhang J, Chen F, Hu X, Wang X. Review of the toxic effects and health functions of arecoline on multiple organ systems. Food Innov Adv. 2024;3(1):31–41.

[16]. Lin W-Y, Chiu C-T, Cheng J-T, et al. Arecoline nitrate induces cardiac fibrosis by disturbing extracellular matrix homeostasis in mice. Open Life Sci. 2021;16(1):1182–92.

[17]. U.S. Department of Health and Human Services. The Health Consequences of Smoking—50 Years of Progress: A Report of the Surgeon General. Atlanta, GA: USDHHS; 2014.

[18]. Hecht SS. Tobacco smoke carcinogens and lung cancer. J Natl Cancer Inst. 1999;91(14):1194–210.

[19]. World Health Organization International Agency for Research on Cancer. Betel-quid and areca-nut chewing carcinogenic to humans (IARC Press Release No.153). WHO/IARC; 2003 Aug 7.

[20]. Boffetta P, Straif K, et al. Smokeless tobacco and cancer. Lancet Oncol. 2008;9(7):667–75.

[21]. Manarangi De Silva G, Panisi L, Brownfoot F, et al. Betel nut use in pregnancy and the risk of adverse perinatal outcomes: a systematic review and meta-analysis. Int J Gynaecol Obstet. 2019;147(3):292–300.

[22]. Kumar A, Oswal K, Singh R, et al. Assessment of areca nut use, practice and dependence among people in Guwahati, Assam: a cross-sectional study. Ecancermedicalscience. 2021;15:1198.